InvestorAndreessen Horowitz, also known as a16z, is a prominent venture capital firm based in Silicon Valley, founded in 2009. The firm invests across various sectors, supporting companies from early-stage startups to growth-stage firms.

Mianus Capital is a life-sciences venture capital firm based in Wisconsin, specializing in early-stage biotechnology investments with a focus on ophthalmology. The firm leverages its partnership with MERIT CRO to enhance its investment strategy.
Online destinations
Where to find this organization online, grouped by who runs each page. A link here does not mean the organization controls it.
Pages the organization runs itself.
Mianus Capital is a specialist life-sciences investment firm founded in 2012 and headquartered in Wisconsin, USA. The organization focuses on Seed and Pre-A investment opportunities in early-stage biotechnology innovation globally. Mianus Capital partners with MERIT CRO, Inc., which provides expertise in drug development and clinical research. The firm emphasizes a diversified portfolio across various therapeutic areas, leveraging insights from its strategic partner, MERIT CRO, to support clinical development. Mianus aims to combine Western biotech innovation with China's clinical ecosystem to accelerate the development of transformative therapies.
Mianus Capital invests in early-stage biotech companies, specifically targeting Seed and Pre-A funding rounds. The firm emphasizes a diversified portfolio across various therapeutic areas, leveraging insights from its strategic partner, MERIT CRO, to support clinical development. The organization aims to combine Western biotech innovation with China's clinical ecosystem to accelerate the development of transformative therapies.
Mianus Capital provides its portfolio companies with access to clinical trial expertise and operational support through its partnership with MERIT CRO, enhancing their ability to navigate the drug development process effectively.
Mianus Capital focuses on early-stage biotech companies, particularly those in Seed and Pre-A funding rounds. The firm emphasizes a diversified portfolio across various therapeutic areas, with a strong interest in ophthalmology.
Founders can reach out to Mianus Capital via email at info@mianuscapital.com. It is advisable to include a detailed pitch deck that outlines the business model, market opportunity, and team background.
Mianus Capital differentiates itself through its strategic partnership with MERIT CRO, which provides clinical trial expertise and operational support. This integration allows Mianus to enhance its investment strategies and support portfolio companies effectively.
The firm has a global investment focus, targeting early-stage biotech opportunities across various regions, including the integration of Western biotech innovation with China's clinical ecosystem.
While specific check sizes are not disclosed, Mianus Capital primarily targets Seed and Pre-A funding rounds, which typically range from hundreds of thousands to several million dollars.
Mianus Capital provides operational support and access to clinical trial expertise through its partnership with MERIT CRO, enhancing the ability of portfolio companies to navigate the drug development process.
Superscout Pro
Is this page right?Reviewed · How the research works